Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00132886 · ClinicalTrials.gov registry record · Phase 2

Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure

A Phase 2 study of Heart Failure, Congestive, sponsored by Otsuka Pharmaceutical Development & Commercialization.

Completed
Registry status
Phase 2
Development phase
140
Enrollment target
20
Study locations

NCT00132886 is a Phase 2 study of Heart Failure, Congestive that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 140 participants, below the 638-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00132886, a Phase 2 study of Heart Failure, Congestive, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.

COMPLETED
Registry status
Phase 2
Development phase
140 participants
Enrollment target
20
Study locations

Study Summary

This study will look at how a single dose of study medication (tolvaptan) versus an inactive sugar pill (placebo) effect pressures in the heart in patients with congestive heart failure. Higher than normal pressures can be related to symptoms of heart failure (shortness of breath, fatigue, etc.).

Conditions Studied

Heart Failure, Congestive

Interventions

  • DRUG tolvaptan

Study Locations (20)

Florida

  • Broward General Medical Center - Fort Lauderdale
  • Cardiovascular Center at Shands Jacksonville - Jacksonville
  • Tampa General Hospital - Tampa

Illinois

  • Northwestern University - Chicago
  • Robert Rush University Medical Center - Chicago
  • Loyola University of Chicago - Maywood

California

  • Merced Heart Associates - Merced
  • Olive View-UCLA Medical Center - Sylmar

Louisiana

  • Cardiologist Institute - Slidell
  • Medical Research Institute Louisiana Heart Hospital - Slidell

Massachusetts

  • Primary Cardiology Associates - Ayer
  • U-MASS Memorial Medical Center - Worchester

Alabama

  • Oracle Research, A Div of the Heart Center - Huntsville

Georgia

  • ACRI - Atlanta

Iowa

  • University of Iowa Health Care - Iowa City

Trial Details

FieldValue
Enrollment Target 140 participants
Start Date 2004-12
Est. Completion 2006-12
Phase Phase 2

Sponsor

Otsuka Pharmaceutical Development & Commercialization

221 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00132886

The ClinicalTrials.gov registry entry for NCT00132886 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 638-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (78% lower). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 1 intervention - of which tolvaptan is the first listed.

NCT00132886 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Illinois, California.

Frequently Asked Questions

What is clinical trial NCT00132886 about?

NCT00132886 is a clinical study titled "Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure". This study will look at how a single dose of study medication (tolvaptan) versus an inactive sugar pill (placebo) effect pressures in the heart in patients with congestive heart failure. Higher than normal pressures can be related to symptoms of heart failure (shortness of breath, fatigue, etc.).

What is the current status of trial NCT00132886?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2004-12. Estimated completion is 2006-12.

What conditions does trial NCT00132886 study?

This clinical trial studies the following conditions: Heart Failure, Congestive.

What interventions are being tested in trial NCT00132886?

The interventions under investigation include: tolvaptan (DRUG).

Who is sponsoring clinical trial NCT00132886?

This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00132886 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure, Congestive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure, Congestive

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.